The global animal biotechnology market size was valued at USD 22.66 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 9.2% from 2022 to 2030. Key growth drivers include the rising need to develop genetically modified therapeutic proteins providing better resistance to diseases, application in cancer treatment, and heightened preventive care for pets. Other aspects contributing to the industry growth comprise improved demand for the usage of animals in agriculture, meat, and animal-based products, growing awareness regarding animal health and welfare, expanding role of animals in the development of pharmaceuticals for humans, and growing animal adoption.
Rising cancer incidence in dogs is further fueling industry growth. As per the National Cancer Institute, nearly 6 million new cancer diagnoses are made in dogs every year. Moreover, the Veterinary Cancer Society projected that 1 in 4 dogs will develop cancer at some point, and almost 50% of dogs over age 10 will develop cancer. The obesity prevalence amongst the pet population is increasing all over the world. Owing to the fact that excess fat and body weight enhances the load on joints, overweightness is directly linked with osteoarthritis in dogs, which results in difficulty in movement. As per Petpedia. co, 30% of all dogs in the U.S. are obese. Therefore, these trends combined with the other factors are anticipated to positively drive the market.
The COVID-19 pandemic crisis has overburdened public health systems in many nations and emphasized the strong requirement for sustainable investment in health systems. The COVID-19 pandemic forced nearly everyone to work remotely. Medium- and small-sized businesses faced difficulties as there are restrictions on vet clinic visits due to the pandemic. Besides, in a globalized world that depends on supply chain logistics, the COVID-19 pandemic and the measures undertaken to curb its spread created bottlenecks. For instance, nations such as Romania have banned the export to Non-European Union nations, thus creating severe demand-supply problems in the animal feed sector. Moreover, the consumption of fish and meat has declined drastically throughout the globe, which, in turn, declined the demand for feed additives, thus impacting the market growth.
An increasing number of initiatives and campaigns are implemented by the government to promote animal health, which may increase the demand for animal health biotechnology in the coming years. For example, in January 2021, the governments of Canada and Ontario are providing up to $4 million through the Canadian Agricultural Partnership to offer farmers improved access to veterinary services when and where they require it. Likewise, TRPVB is a partnership initiative between the Department of Biotechnology, India, and TANUVAS-Chennai to enable a collaborative and coordinated approach to the transformation of technologies in the field of veterinary vaccines, biologicals, and diagnostics.
Innovations and recent advances in immunology, molecular biology, and genetic engineering have expanded the scope of animal health biotechnology. Breakthroughs in molecular marker technology advancements, farm animal genome sequencing, and other biotechnology applications will offer new possibilities for research to enhance and modernize the animal health industry. In December 2021, The Asian Development Bank has signed a contract to take a stake in Zenex Animal Health India Private Limited with an investment of up to $10 million, to expand Zenex’s manufacturing and distribution of quality animal health products. Asian Development Bank will assist Zenex’s investments in maintenance expenditure, working capital, and research and development of new products.
The growing initiative to educate on animal genetic testing is further anticipated to drive the market. For example, the Veterinary Genetics Laboratory at the UC Davis School of Veterinary Medicine has released an updated and improved website along with numerous new tests for the veterinary community. Furthermore, the growing incidence of zoonotic diseases is increasing the demand for advanced diagnosis. Brazil had the second-largest cattle inventory in the world in 2021. In recent months, Zoonoses have dominated the headlines. After the occurrence of a highly contagious and virulent strain of avian flu in Asia and the bovine spongiform encephalopathy (BSE) discovery in the western U.S., tens of millions of birds have been killed and hundreds of cattle slaughtered.
The vaccines segment held the largest revenue share of over 25.0% in 2021. The growth of the vaccine segment is primarily attributed to the increasing burden of animal infections. These infections are naturally transmitted from animals to humans owing to contaminated food and water consumption or direct communication with infected humans or animals. Vaccination is an effective way to lower the disease burden in animals, and it plays an important role in preventive healthcare and disease control. Additionally, the increase in vaccine introductions for animals by the key market players is projected to drive the segment. In December 2021, Indian Immunologicals Ltd. introduced Goat Pox Vaccine (Raksha Goat Pox). Likewise, in May 2021, Boehringer Ingelheim India released its poultry vaccine VAXXITEK HVT+IBD. Such launches will lead to the increased adoption of vaccines, fueling segment growth.
The diagnostics tests segment is anticipated to witness exponential growth throughout the forecast period. The growth in this segment is attributed to factors, such as growing animal health expenditure, rising incidence of zoonotic diseases, increase in the number of veterinary practitioners, and increasing disposable income levels in developing territories. Besides, the overall market is determined by deeply understanding the demand for these products from veterinary hospitals, clinics, labs, etc., and increasing R&D investments from industry players. In August 2021, INDICAL BIOSCIENCE GmbH acquired the Check-Points, Dutch R&D-focused corporation. INDICAL is a global leader in the advancement of complete solutions for molecular and immunological veterinary testing.
The preventive care of animals segment held the largest revenue share of over 25.0% in 2021 due to the growing adoption of companion animals. The advent of pet parents as part of the pet humanization trend is a key revenue-generating trend in the market. Besides, an international survey by HABRI and Zoetis indicates a direct relationship between the human-animal bond and consistent veterinary care. The study including participants from the U.S., France, the U.K., Spain, Germany, Japan, Brazil, and China showed a clear global phenomenon of the improved bond between humans and pets, with 95% of respondents stating that they consider their pets to be a part of the family. Thus, such a human-animal bond advances better preventive care.
The drug development application is anticipated to witness exponential growth throughout the forecast period. Leveraging the monoclonal antibodies in animal health generated great potential to address unmet needs. For instance, in September 2021, Boehringer Ingelheim and Invetx announced that they have entered a collaboration agreement to develop innovative, species-specific monoclonal antibody biotherapeutics targeting a broad range of infections in the veterinary species, primarily focused on dogs and cats. This partnership will address Boehringer Ingelheim’s commitment to delivering unmet needs in the rapidly growing animal health biotechnology market.
The livestock segment held the largest share of over 60.0% in 2021. Livestock is becoming increasingly vital in the growth of agriculture in developing nations. The contributions made by livestock to both agriculture and gross domestic product have risen in various nations. The demand for livestock products is a function of income in different parts of the world. The growing urban population and changes in diet and lifestyle are promoting growth in livestock production, thus contributing to the segment growth. Furthermore, government initiatives undertaken for livestock vaccinations promote market growth.
For instance, in June 2022, Indonesia launched a countrywide livestock vaccination program as the number of cattle affected with foot and mouth disease surged to more than 151,000. In the livestock segment, cattle held the largest revenue share in 2021. The U.S. is home to about 93.8 million cattle and calves as of 2020. The companion animal type segment is likely to grow lucratively during the forecast period owing to an increase in the demand for efficient animal care and the pet-human bond owing to the associated health benefits. Banfield Pet Hospital, in January 2021, confirmed a huge boom in U.S. pet ownership, thus supporting the segment growth.
The veterinary hospitals and clinics segment held the largest revenue share of over 70.0% in 2021 and is anticipated to continue leading the market over the forecast period. The availability of a wide range of treatment and diagnostic options in veterinary hospitals and clinics is a high-impact rendering growth driver for this segment. An increase in the incidence of zoonotic diseases caused by globalization and climate changes is expected to drive the demand for diagnostic procedures, which is expected to drive the point-of-care testing/in-house testing segment in the coming years.
The others segment is expected to witness the fastest growth over the forecast period. Veterinary research institutes and universities are expected to grow at a lucrative rate over the forecast period. This can be attributed to the growing R&D funding to develop advanced diagnostic tools and therapeutically advanced vaccines and medicines. Research institutes are primarily responsible for the development of these diagnostics.
North America accounted for the largest revenue share of over 30.0% in 2021 owing to the high animal awareness levels and improved healthcare infrastructure. The presence of healthcare programs and a rise in the number of initiatives to promote animal health are factors anticipated to increase the growth potential in this region. Moreover, high R&D spending in the region is anticipated to boost market growth in North America. In October 2021, Zoetis Inc. expanded its manufacturing and development facility in Tullamore, Ireland, which substantially expanded its capacity for producing veterinary monoclonal antibodies.
The Asia Pacific market is expected to witness the fastest growth over the forecast period. The rise in middle-class households, increased disposable income, acceptance of pet animals, new product launches, and high demand for animal proteins are some of the key factors expected to boost the growth of the market in the region. In June 2022, India's first COVID-19 vaccine Anocovax for animals unveiled. Besides Anocovac, the Agriculture Minister of India launched the 'CAN-CoV-2 ELISA kit' -- specific nucleocapsid protein-based indirect ELISA kit -- for antibody detection against SARS-CoV-2 in canines.
Major players observed growth during the pandemic despite the restriction and supply chain disruption. Consolidated revenues of Neogen Corporation were USD 418.2 million in fiscal 2020, an upsurge of 1.0% compared to 2019. Multinational companies are investing in increased production capacity, expanding sites in Asia and China; and building more partnerships. Small-to-medium size corporations view emerging nations with growing economies as high-potential markets.
The key players are involved in various strategies such as new product type developments, distribution agreements, and expansion strategies to improve their market penetration. For instance, in March 2022, Hester Biosciences Limited expanded into the Pet Care sector. Likewise, in August 2021, Elanco closed the acquisition of Kindred Biosciences. Additionally, in October 2021, Embark Veterinary, Inc., has released its DNA test for purebred dogs. The kit offers purebred owners exclusive, actionable health information to assist in pinpoint diagnostic, treatment plans, and monitoring that can easily be shared with a veterinarian. Some prominent players in the global animal biotechnology market include:
Zoetis
Boehringer Ingelheim International GmbH
Biogénesis Bagó
Merck & Co., Inc.
Virbac
Elanco
Idexx Laboratories
Heska Corporation
Indian Immunologicals Ltd.
HESTER BIOSCIENCES LIMITED
Kareo, Inc.
NXGN Management, LLC
Report Attribute |
Details |
Market size value in 2022 |
USD 24.20 billion |
Revenue forecast in 2030 |
USD 49.07 billion |
Growth Rate |
CAGR of 9.2% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2017 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product type, application, animal type, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; the Middle East and Africa |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Japan; India; China; Australia; Brazil; Mexico, Argentina; South Africa; Saudi Arabia |
Key companies profiled |
Zoetis; Boehringer Ingelheim International GmbH; Biogénesis Bagó; Merck & Co., Inc.; Virbac; Elanco; Idexx Laboratories; Heska Corporation; Indian Immunologicals Ltd.; HESTER BIOSCIENCES LIMITED |
Customization scope |
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global animal biotechnology market report based on product type, application, animal type, end-use, and region:
Product Type Outlook (Revenue, USD Million, 2017 - 2030)
Diagnostics Tests
Vaccines
Drugs
Reproductive and Genetic
Feed Additives
Application Outlook (Revenue, USD Million, 2017 - 2030)
Diagnosis of Animal Diseases
Treatment of Animal Diseases
Preventive Care of Animals
Drug Development
Others
Animal Type Outlook (Revenue, USD Million, 2017 - 2030)
Companion
Dogs
Cats
Horses
Others
Livestock
Poultry
Swine
Cattle
Sheep & Goats
Fish
End-use Outlook (Revenue, USD Million, 2017 - 2030)
Laboratories
Point-of-Care Testing/In-house Testing
Veterinary Hospitals & Clinics
Others
Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
b. The global Animal Biotechnology market is expected to grow at a compound annual growth rate of 9.2% from 2022 to 2030 to reach USD 49.07 billion by 2030
b. The vaccines segment dominated and accounted for the largest revenue share of over 29.0% in 2021. This is attributable due to easy availability and new improvements by key players
b. Some of the key players in the Animal Biotechnology market are Merck Animal Health; Ceva; Zoetis; Boehringer Ingelheim GmbH; Elanco; Indian Immunologicals Ltd.; Biogénesis Bagó; Phibro Animal Health; among others
b. Key factors that are driving the Animal Biotechnology market growth include the rising prevalence of animal diseases, a surge in the demand for animal protein, and advancements in animal health biotechnology services.
b. The global Animal Biotechnology market size was estimated at USD 22.66 billion in 2021 and is expected to reach USD 24.20 billion in 2022
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."